Analyzing Lexicon Pharmaceuticals (NASDAQ:LXRX) and Williston (OTCMKTS:WHCA)

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Williston (OTCMKTS:WHCA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Volatility and Risk

Lexicon Pharmaceuticals has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Comparatively, Williston has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500.

Institutional & Insider Ownership

74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Lexicon Pharmaceuticals and Williston, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1	0	2	0	2.33
Williston	0	0	0	0	0.00

Lexicon Pharmaceuticals currently has a consensus target price of $4.55, indicating a potential upside of 139.47%. Given Lexicon Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Lexicon Pharmaceuticals is more favorable than Williston.

Earnings and Valuation

This table compares Lexicon Pharmaceuticals and Williston”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$49.80 million	16.95	-$50.34 million	($0.07)	-27.14
Williston	N/A	N/A	N/A	N/A	N/A

Williston has lower revenue, but higher earnings than Lexicon Pharmaceuticals.

Profitability

This table compares Lexicon Pharmaceuticals and Williston’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%
Williston	N/A	N/A	N/A

Summary

Lexicon Pharmaceuticals beats Williston on 6 of the 10 factors compared between the two stocks.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

About Williston

Williston Holding Company, Inc. owns and operates restaurants. The company was incorporated in 2012 and is based in Eden Prairie, Minnesota.